Refine
Year of publication
Document Type
- Preprint (630)
- Article (370)
- Contribution to a Periodical (3)
- Working Paper (2)
Has Fulltext
- yes (1005)
Is part of the Bibliography
- no (1005)
Keywords
- Heavy Ion Experiments (19)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- Heavy-ion collision (6)
- Collective Flow (4)
- Jets (4)
- LHC (4)
- Quark-Gluon Plasma (4)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- ALICE experiment (2)
- COVID-19 (2)
- Charm physics (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Germany (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- QCD (2)
- acute myeloid leukemia (2)
- childhood acute myeloid leukemia (2)
- relapse (2)
- salvage therapy (2)
- 3years (1)
- 900 GeV (1)
- ALICE (1)
- ALICE detector (1)
- ALK-rearranged NSCLC (1)
- Active middle ear implants (1)
- Acute kidney injury (1)
- Alcorrín (1)
- Animal model (1)
- Anti-nuclei (1)
- Auditory system (1)
- Autologous stem cell transplantation (1)
- Beauty production (1)
- Bike-Sharing (1)
- Bipolar disorder (1)
- Blood loss (1)
- Bone conduction devices (1)
- Bone tumor (1)
- Boosted Jets (1)
- Bronce Final (1)
- CTLA-4 (1)
- CVD biomarker (1)
- Car-Sharing (1)
- Centrality Class (1)
- Centrality Selection (1)
- Cleanliness level (1)
- Collective Flow, (1)
- Colloids (1)
- Colon capsule endoscopy (1)
- Complementation rate (1)
- Congenital ocular motor apraxia (1)
- Consensus statement (1)
- Couch tracking (1)
- DME (1)
- DNA methylation (1)
- Deutschland (1)
- Diagnostic markers (1)
- EBV (1)
- Early Iron Age (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Elektromobilität (1)
- Elliptic flow (1)
- Endocrine cancer (1)
- Estrecho de Gibraltar (1)
- Extended donor criteria (1)
- Fibre/foam sandwich radiator (1)
- Flottenkonzepte (1)
- Forschung (1)
- Fortifica (1)
- General relativity (1)
- General relativity equations & solutions (1)
- Gimbaled tracking (1)
- Graft function (1)
- Graft survival (1)
- HES (1)
- HNO (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Health policy (1)
- Heavy Ion Experiment (1)
- Heavy Quark Production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- High-dose chemotherapy (1)
- Hydroxyethyl starch (1)
- ILUVIEN (1)
- IgG4-related disease (1)
- Incomplete colonoscopy (1)
- Indeterminate biliary stricture (1)
- Indigenous Peoples (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Jet Physics (1)
- Jet Substructure (1)
- Joubert syndrome (1)
- Krebsforschung (1)
- LTER (1)
- Ladeinfrastruktur (1)
- Late Bronze Age (1)
- Lehre (1)
- Lenalidomide (1)
- Lepton-Nucleon Scattering (experiments) (1)
- Liver transplantation (1)
- Long‐term ecosystem research (1)
- Low volume prep (1)
- MLC tracking (1)
- Marginal grafts (1)
- Minimum Bias (1)
- Mixed hearing loss (1)
- Mobil-Stationen (1)
- Molar tooth sign (1)
- Monte Carlo (1)
- Moviprep (1)
- Multi-Parton Interactions (1)
- Multi-stakeholder approach (1)
- Multi-wire proportional drift chamber (1)
- Multiple myeloma (1)
- Neural network (1)
- Neuroendocrine cancer (1)
- Next-generation sequencing (1)
- Nucleosynthesis in explosive environments (1)
- ORL (1)
- Organ motion (1)
- Organ rinse (1)
- Organ shortage (1)
- Otorhinolaryngology (1)
- PCR (1)
- PD-1 (1)
- PYTHIA (1)
- Particle and Resonance Production (1)
- Pedelecs (1)
- Phoenician Writing (1)
- Phoenicians (1)
- Phospho-soda (1)
- PillCamColon2 (1)
- Polyps (1)
- Primera Edad del Hierro (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Quark Deconfinement (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- Rabbit (1)
- Radiofrequency ablation (1)
- Rapidity Range (1)
- Rehabilitation (1)
- Relapse (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Research (1)
- Research infrastructure (1)
- Residency (1)
- Resolution Parameter (1)
- Retro-IDEAL (1)
- Robotic tracking (1)
- SARS-CoV-2 (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- Second-line treatment (1)
- Single electrons (1)
- Site networks (1)
- Specialist training (1)
- Steroid (1)
- Strait of Gibraltar (1)
- Surgery (1)
- Systematic Uncertainty (1)
- TP53 mutation status (1)
- TR (1)
- Tacrolimus (1)
- Teaching (1)
- Technical data (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transient & explosive astronomical phenomena (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trauma (1)
- Trigger (1)
- Tumor therapy (1)
- Umweltbilanz (1)
- University hospitals (1)
- Universitätskliniken (1)
- VX-2 (1)
- Vector Boson Production (1)
- Volume therapy (1)
- Weiterbildung (1)
- Xenon-based gas mixture (1)
- adolescents’ health (1)
- advanced melanoma (1)
- allocation (1)
- bile duct stenosis (1)
- biliary stricture (1)
- biofilm (1)
- child (1)
- cholangiocarcinoma (1)
- complete response (1)
- dE/dx (1)
- dental implant (1)
- discontinuation (1)
- disease progression (1)
- ectosomes (1)
- electrolytic cleaning (1)
- endoscopic retrograde cholangiopancreatography (1)
- endoscopy (1)
- eosinophilic cholangitis (1)
- escritura fenicia (1)
- exosomes (1)
- extracellular vesicles (1)
- fenicios (1)
- fortificación, (1)
- fourth (1)
- graft (1)
- guidelines (1)
- heavy ion experiments (1)
- immune checkpoint blockade (1)
- immunohistochemistry (1)
- indígenas (1)
- infection (1)
- kidney (1)
- kidney transplantation (1)
- liver metastasis (1)
- liver transplantation (1)
- loss (1)
- microdosing (1)
- microparticles (1)
- microsatellite instability (1)
- microvesicles (1)
- minimal information requirements (1)
- multidrug resistance (1)
- multisite cooperation (1)
- neutralizing antibodies (1)
- nocardia (1)
- nocardiosis (1)
- paediatric nephrology (1)
- pediatric (1)
- pediatric patients (1)
- periimplantitis (1)
- perio-prosthetic joint infection (1)
- personalized oncology (1)
- pp collisions (1)
- primary sclerosing cholangitis (1)
- pulmonary nocardiosis (1)
- quark gluon plasma (1)
- re-transplantation (1)
- recurrent cholangitis (1)
- repeated (1)
- reproducibility (1)
- research consortium (1)
- rigor (1)
- risk factor progression (1)
- risk factors (1)
- second-line immunotherapy (1)
- sequential ALK-inhibitor therapy (1)
- short-course antibiotic therapy (1)
- spike protein (1)
- standardization (1)
- survival (1)
- targeted therapy (1)
- third (1)
- transfer (1)
- transition (1)
- translational cancer research (1)
- treatment resistance (1)
- uveal melanoma (1)
- variants of concern (1)
Institute
- Physik (954)
- Frankfurt Institute for Advanced Studies (FIAS) (883)
- Informatik (852)
- Medizin (36)
- Informatik und Mathematik (3)
- Präsidium (3)
- Geographie (2)
- Geowissenschaften (2)
- Hochschulrechenzentrum (2)
- Biowissenschaften (1)
Los campañas de 2006, 2007 y 2008 en Alcorrín han puesto de manifiesto la importancia del lugar para los primeros contactos entre fenicios e indígenas en el extremo occidental de la provincia de Málaga, que las dataciones radiométricas han situado en la segunda mitad del siglo IX a.C. Este proyecto ha permitido documentar una imponente fortificación del Bronce Final, conocida con anterioridad sólo a nivel superficial. La realización de prospecciones geofísicas nos revela un incipiente urbanismo que irá siendo conocido en detalle en futuras actuaciones. Estos trabajos se han completado con la excavación de un edificio singular, de planta cuadrangular y compartimentada, con un pavimento de conchas en su acceso. Entre los materiales, escasos y mayoritariamente consistentes en cerámica a mano, cabe señalar la presencia de dos grafitos fenicios sobre cerámica.
Die Fundmeldungen in Band 33 von Botanik und Naturschutz in Hessen stammen von: Dirk Bönsel, Martin de Jong, Wolfgang Ehmke, Peter Emrich, Benjamin Feller, Brunhilde Göbel, Thomas Gregor, Arthur Händler, Sylvain Hodvina, Gerwin Kasperek, Egbert Korte, Ute Lange, Stefan Meyer, Hasko Friedrich Nesemann, Uwe Raabe, Bernd Sauerwein, Marco Schmidt, Christof Nikolaus Schröder, Antje Schwab, Rainer Stoodt und Michael Uebeler.
Survival following relapse in children with Acute Myeloid leukemia: a report from AML-BFM and COG
(2021)
Simple Summary: Acute myeloid leukemia in children remains a difficult disease to cure despite intensive therapies that push the limits of tolerability. Though the intent of initial therapy should be the prevention of relapse, about 30% of all patients experience a relapse. Hence, relapse therapy remains critically important for survival. This retrospective analysis of two large international study groups (COG and BFM) was undertaken to describe the current survival, response rates and clinical features that predict outcomes. We demonstrate that children with relapsed AML may be cured with cytotoxic therapy followed by HSCT. High-risk features at initial diagnosis and early relapse remain prognostic for post-relapse survival. Current response criteria are not aligned with the standards of care for children, nor are the count recovery thresholds meaningful for prognosis in children with relapsed AML. Our data provide a new baseline for future treatment planning and will allow an updated stratification in upcoming studies.
Abstract: Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We evaluated survival, response and prognostic variables following relapse in independent cooperative group studies conducted by COG and the population-based AML-BFM study group. BFM included 197 patients who relapsed after closure of the last I-BFM relapse trial until 2017, while COG included 852 patients who relapsed on the last Phase 3 trials (AAML0531, AAML1031). Overall survival at 5 years (OS) was 42 ± 4% (BFM) and 35 ± 2% (COG). Initial high-risk features (BFM 32 ± 6%, COG 26 ± 4%) and short time to relapse (BFM 29 ± 4%, COG 25 ± 2%) predicted diminished survival. In the BFM dataset, there was no difference in OS for patients who had a complete remission with full hematopoietic recovery (CR) following post-relapse re-induction compared to those with partial neutrophil and platelet recovery (CRp and CRi) only (52 ± 7% vs. 63 ± 10%, p = 0.39). Among 90 patients alive at last follow-up, 87 had received a post-relapse hematopoietic stem cell transplant (HSCT). OS for patients with post-relapse HSCT was 54 ± 4%. In conclusion, initial high-risk features and early relapse remain prognostic. Response assessment with full hematopoietic recovery following initial relapse therapy does not predict survival. These data indicate the need for post-relapse risk stratification in future studies of relapse therapies.
Simple Summary: Children with acute myeloid leukemia (AML) experience high relapse rates of about 30%; still, survival rates following the first relapse are encouraging. Hence, it is critically important to examine the consequences of a second relapse; however, little is known about this subgroup of patients. This retrospective population-based analysis intends to describe response, survival and prognostic factors relevant for the survival of children with second relapse of AML. Treatment approaches include many different therapeutic regimens, including palliation and intensive treatment with curative intent (63% of the patients). Survival is poor; however, patients who respond to reinduction attempts can be rescued with subsequent hematopoietic stem cell transplantation. We deciphered risk factors, such as short time interval from first to second relapse below one year as being associated with a poor outcome. This analysis will help to improve future international treatment planning and patient care of children with advanced AML.
Abstract: Successful management of relapse is critical to improve outcomes of children with acute myeloid leukemia (AML). We evaluated response, survival and prognostic factors after a second relapse of AML. Among 1222 pediatric patients of the population-based AML-Berlin–Frankfurt–Munster (BFM) study group (2004 until 2017), 73 patients met the quality parameters for inclusion in this study. Central review of source documentation warranted the accuracy of reported data. Treatment approaches included palliation in 17 patients (23%), intensive therapy with curative intent (n = 46, 63%) and other regimens (n = 10). Twenty-five patients (35%) received hematopoietic stem cell transplantation (HSCT), 21 of whom (88%) had a prior HSCT. Survival was poor, with a five-year probability of overall survival (pOS) of 15 ± 4% and 31 ± 9% following HSCT (n = 25). Early second relapse (within one year after first relapse) was associated with dismal outcome (pOS 2 ± 2%, n = 44 vs. 33 ± 9%, n = 29; p < 0.0001). A third complete remission (CR) is required for survival: 31% (n = 14) of patients with intensive treatment achieved a third CR with a pOS of 36 ± 13%, while 28 patients (62%) were non-responders (pOS 7 ± 5%). In conclusion, survival is poor but possible, particularly after a late second relapse and an intensive chemotherapy followed by HSCT. This analysis provides a baseline for future treatment planning.
Die Fundmeldungen in Band 34 von Botanik und Naturschutz in Hessen stammen von: Dirk Bönsel, Martin De Jong, Klaus Dühr, Uta Engel, Benjamin Feller, Christian Feuring, Thomas Gregor, Arthur Händler, Karsten Horn, Diemut Klärner, Julia Kruse, Eric Martiné, Hasko Friedrich Nesemann, Kai Uwe Nierbauer, Uwe Raabe, Susanne Raehse, Felix Reischmann, Bernd Sauerwein, Petra Schmidt, Fabian Schrauth, Christof Nikolaus Schröder, Helmut Siebert, Michael Thieme, Otto Wacker und Rüdiger Wittig.
Global change effects on biodiversity and human wellbeing call for improved long-term environmental data as a basis for science, policy and decision making, including increased interoperability, multifunctionality, and harmonization. Based on the example of two global initiatives, the International Long-Term Ecological Research (ILTER) network and the Group on Earth Observations Biodiversity Observation Network (GEO BON), we propose merging the frameworks behind these initiatives, namely ecosystem integrity and essential biodiversity variables, to serve as an improved guideline for future site-based long-term research and monitoring in terrestrial, freshwater and coastal ecosystems. We derive a list of specific recommendations of what and how to measure at a monitoring site and call for an integration of sites into co-located site networks across individual monitoring initiatives, and centered on ecosystems. This facilitates the generation of linked comprehensive ecosystem monitoring data, supports synergies in the use of costly infrastructures, fosters cross-initiative research and provides a template for collaboration beyond the ILTER and GEO BON communities.
Background: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM has improved. However, it is unclear how the presence of hepatic and extrahepatic metastasis impacts the response and survival after ICB. Methods: A total of 178 patients with metastatic UM treated with ICB were included in this analysis. Patients were recruited from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of hepatic metastasis, two cohorts were compared: patients with liver metastasis only (cohort A, n = 55) versus those with both liver and extra-hepatic metastasis (cohort B, n = 123). Data were analyzed in both cohorts for response to treatment, progression-free survival (PFS), and overall survival (OS). The survival and progression probabilities were calculated with the Kaplan–Meier method. Log-rank tests, χ2 tests, and t-tests were performed to detect significant differences between both cohorts. Results: The median OS of the overall population was 16 months (95% CI 13.4–23.7) and the median PFS, 2.8 months (95% CI 2.5–3.0). The median OS was longer in cohort B than in cohort A (18.2 vs. 6.1 months; p = 0.071). The best objective response rate to dual ICB was 13.8% and to anti-PD-1 monotherapy 8.9% in the entire population. Patients with liver metastases only had a lower response to dual ICB, yet without significance (cohort A 8.7% vs. cohort B 16.7%; p = 0.45). Adverse events (AE) occurred in 41.6%. Severe AE were observed in 26.3% and evenly distributed between both cohorts. Conclusion: The survival of this large cohort of patients with advanced UM was more favorable than reported in previous benchmark studies. Patients with both hepatic and extrahepatic metastasis showed more favorable survival and higher response to dual ICB than those with hepatic metastasis only.